• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. ResQ Pharma Raises $725,000 and Scheduled to Meet FDA September 29th 2016

    ResQ Pharma Raises $725,000 and Scheduled to Meet FDA September 29th 2016

  2. ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

    ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

  3. U.S. FDA Approves Labeling Update of REXULTI® (brexpiprazole) For Maintenance Treatment of Schizophrenia

    U.S. FDA Approves Labeling Update of REXULTI® (brexpiprazole) For Maintenance Treatment of Schizophrenia

  4. FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update

    FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update

  5. FDA Approves Amgen's Biosimilar Version of Humira -- Update

    FDA Approves Amgen's Biosimilar Version of Humira -- Update

  6. FDA Approves Amgen's Biosimilar Version of Humira

    FDA Approves Amgen's Biosimilar Version of Humira

  7. FDA  Clears Way for ClearRead CT Software

    FDA  Clears Way for ClearRead CT Software

  8. Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

    Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

  9. UPDATE: 5 things we still don't know about EpiPen pricing after Mylan's congressional beating

    UPDATE: 5 things we still don't know about EpiPen pricing after Mylan's congressional beating

  10. UPDATE: 5 things we still don't know about EpiPen pricing after Mylan's congressional beating

    UPDATE: 5 things we still don't know about EpiPen pricing after Mylan's congressional beating

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.